Who makes TOP1630 0.1% Ophthalmic Solution TID OU?

TOP1630 0.1% Ophthalmic Solution TID OU is developed by Topivert Pharma Ltd.

What development phase is TOP1630 0.1% Ophthalmic Solution TID OU in?

TOP1630 0.1% Ophthalmic Solution TID OU is in Phase 2.

Last reviewed 2026-04-19 · How we verify

TOP1630 0.1% Ophthalmic Solution TID OU

Topivert Pharma Ltd · Phase 2 active Small molecule

At a glance

Generic name	TOP1630 0.1% Ophthalmic Solution TID OU
Sponsor	Topivert Pharma Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of TOP1630 for Dry Eye Syndrome (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TOP1630 0.1% Ophthalmic Solution TID OU CI brief — competitive landscape report
TOP1630 0.1% Ophthalmic Solution TID OU updates RSS · CI watch RSS
Topivert Pharma Ltd portfolio CI